晚期结直肠癌中易被忽视的RET融合小亚群
本病例系列比较24例RET重排转移性结直肠癌(mCRC)与291例RET阴性患者的临床、病理及分子特征,病例经系统文献复习及三个筛查来源获取。RET融合多见于老年、ECOG PS 1-2、右侧、原发灶未切除、RAS与BRAF野生型及MSI-high肿瘤,且与更短总生存显著相关。
要点
- RET融合在mCRC中罕见,但右侧且RAS/BRAF野生型者中占比可观。
- RET融合阳性mCRC常规治疗预后差,中位OS为14.0个月。
- 多变量模型中RET重排仍与更短OS独立相关。
核心结论
- RET重排虽罕见,但定义了一个常规治疗预后差、值得专门管理的mCRC新亚型。
研究设计与样本
- 病例系列研究,比较24例RET重排mCRC与291例RET阴性对照。
- 病例通过系统文献复习及Ignyta RXDX-105一期研究、意大利与韩国机构筛查队列、Foundation Medicine数据库获取。
- 对RET重排病例分析下一代测序数据。
主要发现
- RET融合患者中位年龄66岁对60岁(P=0.052)。
- ECOG PS 1-2占90%对50%(P=0.02),右侧占55%对32%(P=0.013)。
- 原发灶未切除占58%对21%(P<0.001),RAS与BRAF野生型占100%对40%(P<0.001),MSI-high占48%对7%(P<0.001)。
- 43例右侧且RAS/BRAF野生型患者中11例(26%)携带RET重排。
- 中位随访45.8个月,RET融合阳性者中位OS为14.0个月对38.0个月(HR 4.59;95%CI 3.64-32.66;P<0.001)。
关键数值与推荐
- 多变量模型中RET重排与更短OS相关(HR 2.97;95%CI 1.25-7.07;P=0.014),而原发部位、RAS/BRAF突变及MSI状态不显著。
临床怎么用
- 对右侧、RAS与BRAF野生型mCRC应考虑RET融合检测以避免漏诊。
- RET融合阳性mCRC预后差,应纳入特定管理策略。
局限性
- 为病例系列设计,RET重排与对照病例来自文献复习及多个筛查来源,可能存在选择偏倚。
- RET重排样本量较小(24例),结论需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recognition of rare molecular subgroups is a challenge for precision oncology and may lead to tissue-agnostic approval of targeted agents. Here we aimed to comprehensively characterize the clinical, pathological and molecular landscape of RET rearranged metastatic colorectal cancer (mCRC). PATIENTS AND METHODS: In this case series, we compared clinical, pathological and molecular characteristics of 24 RET rearranged mCRC patients with those of a control group of 291 patients with RET negative tumors. RET rearranged and RET negative mCRCs were retrieved by systematic literature review and by taking advantage of three screening sources: (i) Ignyta's phase 1/1b study on RXDX-105 (NCT01877811), (ii) cohorts screened at two Italian and one South Korean Institutions and (iii) Foundation Medicine Inc. database. Next-generation sequencing data were analyzed for RET rearranged cases. RESULTS: RET fusions were more frequent in older patients (median age of 66 versus 60 years, P = 0.052), with ECOG PS 1-2 (90% versus 50%, P = 0.02), right-sided (55% versus 32%, P = 0.013), previously unresected primary tumors (58% versus 21%, P < 0.001), RAS and BRAF wild-type (100% versus 40%, P < 0.001) and MSI-high (48% versus 7%, P < 0.001). Notably, 11 (26%) out of 43 patients with right-sided, RAS and BRAF wild-type tumors harbored a RET rearrangement. At a median follow-up of 45.8 months, patients with RET fusion-positive tumors showed a significantly worse OS when compared with RET-negative ones (median OS 14.0 versus 38.0 months, HR: 4.59; 95% CI, 3.64-32.66; P < 0.001). In the multivariable model, RET rearrangements were still associated with shorter OS (HR: 2.97; 95% CI, 1.25-7.07; P = 0.014), while primary tumor location, RAS and BRAF mutations and MSI status were not. CONCLUSIONS: Though very rare, RET rearrangements define a new subtype of mCRC that shows poor prognosis with conventional treatments and is therefore worth of a specific management.
引用
- Pietrantonio F, Di Nicolantonio F, Schrock AB, et al. RET fusions in a small subset of advanced colorectal cancers at risk of being neglected. Ann Oncol. 2018. PMID: 29538669. doi:10.1093/annonc/mdy090
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。